Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genfar

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

Ageing Asia: What does this mean for the future of healthcare?

Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population. This has contributed to declining fertility and increasing...

Research Partnership

- PMLiVE

NICE backs Sanofi’s Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

Sanofi reception

Sanofi, Regeneron claim EU approval for eczema drug Dupixent

Analysts suggest the product could be worth €5bn at peak

Life lessons

The recent problems of the generics sector have lessons for research-based companies too

- PMLiVE

Sanofi looks to mobile data to power behavioural analysis

Teams up with Evidation Health for a new digital health partnership

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

Research Partnership

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two...

Research Partnership

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global...

Research Partnership

Sanofi reception

Solid start for Dupixent as Sanofi raises 2017 outlook

Analysts predict dermatology medicine could become a €5bn product if approved in other indications

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links